About Parvus Therapeutics
Parvus Therapeutics is a company based in Burlingame (United States) founded in 2009 by Pere Santamaria. Parvus Therapeutics offers products and services including pMHC Nanomedicine and Pipeline Platform. Parvus Therapeutics operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Cellino, among others.
- Headquarter Burlingame, United States
- Founders Pere Santamaria
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Parvus Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Parvus Therapeutics
Parvus Therapeutics offers a comprehensive portfolio of products and services, including pMHC Nanomedicine and Pipeline Platform.
Generates regulatory T cells to treat autoimmune diseases without immune suppression.
Supports development of nanomedicine for autoimmune therapies.
People of Parvus Therapeutics
Unlock access to complete
Leadership Team
5 people
Operations Team
2 people
Founder Team
1 people
Finance and Accounting
1 people
Unlock access to complete
Funding Insights of Parvus Therapeutics
Detailed funding history for Parvus Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Parvus Therapeutics
Investment portfolio details for Parvus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Parvus Therapeutics
Detailed financials for Parvus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Parvus Therapeutics Comparisons
Peer comparison for Parvus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Parvus Therapeutics
Parvus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Cellino, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
Detailed competitors of Parvus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Parvus Therapeutics
Complete news archive for Parvus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Parvus Therapeutics
Parvus Therapeutics was founded in 2009.
Parvus Therapeutics is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Curtis Ruegg is the current CEO of Parvus Therapeutics.
Parvus Therapeutics was founded in 2009 and is based in Burlingame, United States, within the biotechnology sector. Focus is placed on creating treatments for autoimmune conditions through the Navacim platform, which employs peptide-MHC-coated nanoparticles to enhance auto-regulatory memory T cells. These cells are directed to eliminate specific antigen-presenting cells, avoiding widespread immunosuppression. Potential uses span type 1 diabetes, liver disorders, inflammatory bowel diseases, and multiple sclerosis.
Parvus Therapeutics's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Parvus Therapeutics offers pMHC Nanomedicine and Pipeline Platform.